Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells

Scholarly Works

• Nanthaprakash, T.; Gourlay, C. W.; Oehme, I.; Garrett, M. D.; Cinatl, J.; Wass, M. N.; Michaelis, M. Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines. Cold Spring Harbor Laboratory 2024. doi:10.1101/2024.10.29.620819
• Cirillo, G.; Cappello, A. R.; Curcio, M.; Fiorillo, M.; Frattaruolo, L.; Avena, P.; Scorzafave, L.; Dolce, V.; Nicoletta, F. P.; Iemma, F. Novel CD44-Targeted Albumin Nanoparticles: An Innovative Approach to Improve Breast Cancer Treatment. International journal of molecular sciences 2024, 25, 10560. doi:10.3390/ijms251910560
• Çetin Altındal, D. Therapeutic potential of boron-based nanoparticles for enhanced glioblastoma treatment. Journal of Drug Delivery Science and Technology 2024, 99, 105936. doi:10.1016/j.jddst.2024.105936
• Mrunalini, B.; Dev, A.; Kushwaha, A. C.; Sardoiwala, M. N.; Karmakar, S. Encapsulation of 4-oxo-N-(4-hydroxyphenyl) retinamide in human serum albumin nanoparticles promotes EZH2 degradation in preclinical neuroblastoma models. Nanoscale 2024, 16, 16075–16088. doi:10.1039/d4nr00642a
• Ganguly, S. C.; Mahanti, B.; Ganguly, S.; Majumdar, S. Bovine serum albumin as a nanocarrier for efficient encapsulation of hydrophobic garcinol-A strategy for modifying the in vitro drug release kinetics. International journal of biological macromolecules 2024, 278, 134651. doi:10.1016/j.ijbiomac.2024.134651
• Asrorov, A. M.; Mukhamedov, N.; Kayumov, M.; Sh. Yashinov, A.; Wali, A.; Yili, A.; Mirzaakhmedov, S. Y.; Huang, Y. Albumin is a reliable drug-delivering molecule: Highlighting points in cancer therapy. Medicine in Drug Discovery 2024, 22, 100186. doi:10.1016/j.medidd.2024.100186
• Babunagappan, K. V.; Seetharaman, A.; Ariraman, S.; Santhosh, P. B.; Genova, J.; Ulrih, N. P.; Sudhakar, S. Doxorubicin loaded thermostable nanoarchaeosomes: a next-generation drug carrier for breast cancer therapeutics. Nanoscale advances 2024, 6, 2026–2037. doi:10.1039/d3na00953j
• Podolski-Renić, A.; Čipak Gašparović, A.; Valente, A.; López, Ó.; Bormio Nunes, J. H.; Kowol, C. R.; Heffeter, P.; Filipović, N. R. Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer. European journal of medicinal chemistry 2024, 270, 116363. doi:10.1016/j.ejmech.2024.116363
• Grimsley, H. E.; Antczak, M.; Reddin, I. G.; McLaughlin, K.-M.; Nist, A.; Mernberger, M.; Stiewe, T.; Fenton, T. R.; Speidel, D.; Harper-Wynne, C.; Cox, K.; Cinatl, J.; Wass, M. N.; Garrett, M. D.; Michaelis, M. Resistance patterns in drug-adapted cancer cell lines reflect the complex evolution in clinical tumours. Cold Spring Harbor Laboratory 2024. doi:10.1101/2024.01.20.576412
• Altındal, D. Therapeutic Potential of Boron-Based Nanoparticles for Enhanced Glioblastoma Treatment. Elsevier BV 2024. doi:10.2139/ssrn.4784885
• Verma, R.; Akter, R.; Kumar, M.; Bhatt, S.; Tiwari, A.; Tiwari, V.; Tagde, P.; Pandey, P.; Mittal, V.; Purohit, D.; Redhu, R.; Rahman, M. H.; Kaushik, D. Exploring the Role of Nanotherapeutics for Diagnosis and Treatment of Solid Tumor. Current Nanoscience 2024, 20, 109–129. doi:10.2174/1573413719666230110124509
• Karami, E.; Mesbahi Moghaddam, M.; Kazemi-Lomedasht, F. Use of Albumin for Drug Delivery as a Diagnostic and Therapeutic Tool. Current pharmaceutical biotechnology 2024, 25, 676–693. doi:10.2174/1389201024666230807161200
• Patel, R.; Kuwar, U.; Dhote, N.; Alexander, A.; Nakhate, K.; Jain, P.; Ajazuddin. Natural Polymers as a Carrier for the Effective Delivery of Antineoplastic Drugs. Current drug delivery 2024, 21, 193–210. doi:10.2174/1567201820666230112170035
• Lee, J.; Choi, M.-K.; Song, I.-S. Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting. Pharmaceuticals (Basel, Switzerland) 2023, 16, 802. doi:10.3390/ph16060802
• Sandha, K. K.; Behera, C.; Chibber, P.; Kumar, R.; Kumar, A.; Mondhe, D. M.; Singh, G.; Gupta, P. N. Antifibrotic Agent Mediated Tumor Microenvironment Modulation and Improved Nanomedicine Delivery in Solid Tumor. Molecular pharmaceutics 2023, 20, 2927–2941. doi:10.1021/acs.molpharmaceut.2c01081
• Kulkarni, S. Natural Polymers-Based Nanoparticles Targeted to Solid Tumors. Environmental Chemistry for a Sustainable World; Springer International Publishing, 2022; pp 75–102. doi:10.1007/978-3-031-14848-4_3
• Paul, M.; Itoo, A. M.; Ghosh, B.; Biswas, S. Current trends in the use of human serum albumin for drug delivery in cancer. Expert opinion on drug delivery 2022, 19, 1449–1470. doi:10.1080/17425247.2022.2134341
• Sharma, P.; Hasan, M. R.; Narang, J. Bio-inspired Protein-Based Nanoparticles in Cancer Therapy. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects; Springer Nature Singapore, 2022; pp 2917–2939. doi:10.1007/978-981-16-5422-0_130
• Sarkar, M.; Wang, Y.; Ekpenyong, O.; Liang, D.; Xie, H. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2022, 15, e1846. doi:10.1002/wnan.1846
• Kulig, K.; Ziąbka, M.; Pilarczyk, K.; Owczarzy, A.; Rogóż, W.; Maciążek-Jurczyk, M. Physicochemical Study of Albumin Nanoparticles with Chlorambucil. Processes 2022, 10, 1170. doi:10.3390/pr10061170

Explore citations to this article at